Dr. Janet Woodcock, director of the Center for Drug Evaluation and Research spoke to the House of Representatives about patient perspective.
Patient advocacy is a vital component in assuring that roadblocks to optimal treatment do not prevent cancer patients from obtaining the help they deserve. Recently, a group from Parent Project Muscular Dystrophy presented the FDA [...]
Personalized or targeted medicine is the paradigm of the future: treatment options customized for individual patients.
Living with GIST can be stressful. There are many coping mechanisms to deal with chronic disease, but one that you may not have used in the past is one that others coping with stress have found enormously helpful: writing.
A recent article from FierceBiotech announced that theAnti-PD-1 cancer drug nivolumab, a fully human antibody, received regulatory approval in Japan.
Marshall Summar, MD to testify on behalf of NORD at 21st Century Cures Hearing in Washington, D. C. on Friday, July 11 at 9 AM ET.
Coverage of GIST Awareness Day continues with this press release that calls attention to our awareness campaign and our support for the global GIST community.
As the cost of cancer treatment rises, so does the anxiety level of those diagnosed. The University of Chicago has developed a tool to assess the financial pain of cancer treatment. In the July issue of [...]
Charlie Burke has developed a thick skin when it comes to cancer. After surviving bouts with colorectal, thyroid and skin cancers, he was well acquainted with the routine of doctor’s appointments, hospital visits, surgeries and regular treatment that accompany disease by the time a GIST tumor was discovered in his colon. However, as any of our members will tell you, GIST comes with its own unique lexicon to master and set of challenges to overcome.
In a recently published article in Nature Genetics, several prominent cancer researchers and GIST experts, led by Dr. Dr. Yuexiang Wang and including Dr. Jonathan Fletcher of Brigham & Women’s Hospital and Dr. Matthew van de Rijn of Stanford University Center, who are both members of the LRG’s research team, discuss new research findings that may potentially help identify GIST patients with a future high risk for metastases.